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A process of pseudomitosis occurs during human cytomegalovirus infection that appears similar to cellular mitosis but
involves the formation of multiple spindle poles, abnormal condensation, and mislocalization of chromosomal DNA.
The relationship of this process to viral replication and cell cycle regulation during infection has been poorly
understood. Pseudomitosis consistently peaks at late times of infection in all viral strains examined but at overall
highest frequencies (30% to 35% of cells) using one common laboratory strain variant (AD169varATCC). Cyclin-
dependent kinase 1 (Cdk1) plays a crucial role in pseudomitosis, mirroring its role in conventional mitosis. Dominant
negative Cdk1 inhibits and wild-type Cdk1 stimulates this process; however, viral yields remain the same regardless of
pseudomitosis levels. Broad inhibition of cell cycle regulated kinases (Cdk1/Cdk2/Cdk5/Cdk9) with indirubin-39-
monoxime substantially decreases viral yields and synergizes with the viral UL97 kinase inhibitor, maribavir. Thus,
Cdk1 is necessary and sufficient to drive pseudomitosis, whereas a combination of viral and cell cycle regulated
kinases is important during viral replication.
Citation: Hertel L, Chou S, Mocarski ES (2007) Viral and cell cycle–regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog 3(1): e6. doi:10.
1371/journal.ppat.0030006
Introduction
DNA viruses have yielded many insights into cell cycle
control as well as regulation of cellular processes associated
with oncogenesis because they encode regulatory proteins
that modulate cell cycle progression and cell death. Members
of the papillomavirus, polyomavirus, hepadnavirus, and
herpesvirus families all cause persistent/latent infections,
and, regardless of any contribution to malignancy, all of
these viruses encode functions that dysregulate cellular
growth, inhibit immune activation, and modulate inﬂamma-
tion [1]. Lifelong infection with human herpesviruses,
including herpes simplex virus (HSV)-1, HSV-2, varicella
zoster virus, Epstein-Barr virus, cytomegalovirus (CMV),
human herpesvirus 6A, 6B, or 7, and Kaposi sarcoma associ-
ated herpesvirus , is associated with dysregulation of the cell
cycle as well as with medically important opportunistic
disease [2,3]. The mechanisms of cell cycle dysregulation in
herpesvirus replication and proliferative disease remain
poorly understood even though these processes underlie
pathogenesis.
Human CMV has a dramatic stimulatory impact on
permissive cells in culture, as typically demonstrated by
infecting human ﬁbroblasts (HFs). Stimulation follows a
bimodal pattern, with an initial peak due to the impact virus
binding and penetration, and a later peak coinciding with
viral DNA synthesis, assembly and release [4–7]. This late
phase of infection is also associated with dysregulation of host
cell cyclin levels and with disruption of cell cycle progression
[8–11] and suggests that these processes are linked. Viral DNA
replication and cell cycle dysregulation both depend upon
expression of viral immediate-early (IE, or a) and delayed-
early (DE, or b) gene products, which precede expression of
late genes and release of progeny virus [6]. This pattern also
implicates early viral gene products in cell cycle stimulation
and dysregulation [5,12] in a manner reminiscent of
oncogene-encoding, DNA tumor viruses [13]. Although
infected cells exhibit a pattern of protein expression
consistent with continued cell cycle progression, normal
cellular prereplication complexes fail to form [14], cellular
DNA synthesis (S phase) fails to proceed [8–11], and
chromosome segregation and cytokinesis are blocked [8–11].
These investigations showed that infected HFs become
arrested in a pseudo-G1 state associated with dramatic
modulation of p53, pRb, cyclins, and cyclin-dependent
kinases (Cdks) in ways that may be critical for viral replication
efﬁciency.
The importance of cell cycle–regulated kinases in CMV
replication is consistent with a strong antiviral impact of
selective Cdk inhibitors such as roscovitine [15]. Roscovitine,
as well as other Cdk inhibitors such as olomucine and
ﬂavopiridol, inhibits herpesviruses, as well as other DNA
viruses and retroviruses, in a pattern that reveals the
underlying importance of host cell protein kinases in viral
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cyclin A in mammalian cells to control G1/S transition.
Although cyclin A expression is suppressed [9–11], cyclin E is
induced and Cdk2/cyclin E activity is increased [9,17,18] in
CMV-infected cells. Most dramatically, the G2/M-associated
Cdk1/cyclin B1 complex is induced [8–11] and accumulates at
late times of CMV infection [14]. The activity of a wide range
of other cell cycle regulators, speciﬁc kinases, and cytoskeletal
proteins is also altered, and some of these proteins are
suspected to function [19–21] during infection [14]. A
systematic analysis of cellular gene transcription patterns
during infection with a commonly used laboratory strain of
CMV (AD169varATCC), provided evidence of extensive cell
cycle dysregulation during the late phase of infection, with a
peculiar transcriptional enhancement of multiple M-phase
regulatory genes [7]. Direct evaluation of infected cultures
unveiled the formation of cells with multipolar mitotic
spindles and abnormally condensed and misaligned chromo-
somes, starting by 2 d postinfection. This abnormal process
was morphologically distinguishable from conventional mi-
tosis and appeared to represent uncontrolled duplication of
centrosomes and aberrant condensation of nonduplicated
cellular DNA into mitotic structures [7]. The Cdk1/cyclin B1
complex is a central regulator of entry into M-phase, which
ensures the correct segregation of chromosomes into
daughter cells at cytokinesis. Regulation of this complex is
achieved through the timed synthesis and degradation of
cyclin B1 and the tight control of Cdk1 phosphorylation state
[22,23]. The elevated Cdk1 and cyclin B1 levels [9,17,18]
observed in CMV-infected cells may thus be directly
responsible for the induction of pseudomitosis.
The Cdk inhibitor indirubin, the active component of the
traditional Chinese anti-inﬂammatory, antibacterial, and
antiviral preparation Danggui Longhui Wan, has also been
used to block cell cycle progression [24–26] but has not been
evaluated during CMV replication. Indirubin and derivatives
such as indirubin-39-monoxime (IMO), which exhibits im-
proved solubility and cell adsorption qualities, have been
used to treat patients suffering from chronic myelocytic or
chronic granulocytic leukemias [27]. The antiproliferative
properties of this compound depend on high afﬁnity
competition for the ATP binding site of Cdk1, Cdk2, and
Cdk5 [28], as well as Cdk9 [29]. IMO induces cell cycle arrest
at both the G1/S and G2/M borders, consistent with blocking
Cdk2/cyclin E and Cdk1/cyclin B1 activities in cultured cells
[28] and animal models [30].
Speciﬁc inhibition of Cdk1 and Cdk2 activity provided
compelling evidence for the function of these kinases at
speciﬁc stages of the cell cycle. Dominant negative, kinase-
inactive Cdk1 arrests cycling cells at the G2/M border, while
dominant negative Cdk2 inhibits G1/S progression [31]. The
reported inhibition of CMV infection by dominant negative
Cdk2 [15] is consistent with a role for this S phase kinase in
viral replication.
In addition to relying on cellular Cdks, CMV encodes the
herpesvirus-conserved viral protein kinase (VPK) ppUL97, a
serine/threonine kinase that plays an important role during
CMV replication [32–35]. Mutation of VPK slows viral DNA
replication and maturation events in a manner that depends
upon cell state and culture conditions. VPK autophosphor-
ylates and potentially acts on viral substrates, such as the
CMV DNA polymerase processivity subunit ppUL44, as well
as cellular substrates, including the largest subunit of RNA
polymerase II and histone H2B [36,37]. VPK phosphorylates
in ways that may overlap with cellular Cdks, is required for
activation of the antiviral drug ganciclovir [38–40], and is the
target of the selective antiviral drug maribavir (MBV, also
called 1263W94) [41,42]. Cells infected with wild-type virus in
the presence of MBV or with UL97 mutant exhibit defects in
viral replication starting at DNA synthesis and extending
through late maturation events [32–35].
Whether pseudomitosis is controlled by viral or cellular
functions and how this process contributes to viral repli-
cation remain unexplored, although observations on infected
cells are consistent with some role for elevated Cdk1/cyclin B1
complex activity. Here we show that induction of pseudomi-
tosis is a common property of CMV strains but is not a
requisite for replication. Pseudomitosis is speciﬁcally de-
pendent on Cdk1 activity, while viral replication requires a
broader set of Cdks acting in concert with VPK.
Results
Pseudomitosis Is a Common Feature of CMV-Infected
Cultures
To determine whether pseudomitosis observed during
infection with a previously evaluated CMV strain variant
(AD169varATCC) [7] was a universal feature of commonly
used CMV strains, we recorded the percentage of pseudomi-
totic cells induced in HFs infected at a multiplicity of
infection (MOI) of 10 with AD169varATCC, AD169varDE,
Toledo, TownevarATCC, TownevarRIT, or TB40/E for 50, 72
and 96 h (Figure 1). Pseudomitotic cells were identiﬁed by
staining infected cultures for the viral nuclear antigens IE1/
IE2 and for the mitotic spindle pole-localizing protein c-
tubulin 1, as described [7]. All strains showed the ability to
drive infected cells into pseudomitosis, albeit with different
efﬁciencies and following different temporal patterns. As
expected, AD169varATCC induced abnormal numbers of
mitotic spindles and misalignment of condensed chromoso-
mal DNA in approximately 35% of infected cells, peaking at
72 h postinfection [7], while all other CMV strains induced
pseudomitosis at lower overall levels. Surprisingly, another
AD169 strain variant (AD169varDE) induced much lower
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Author Summary
The human herpesvirus cytomegalovirus, which infects most people
worldwide, orchestrates a stimulatory effect on cell growth and
division, creating an environment that appears similar to many
cancer-causing viruses that may be important in viral disease. In
previous work, we discovered that viral infection stimulates cells to
proceed to an abnormal state mimicking cell division or mitosis but
blocks the formation of daughter cells. Here the abnormal state
(pseudomitosis) is shown to depend on viral events that drive high
levels of the cellular enzyme cyclin-dependent kinase 1 (Cdk1),
normally associated with progression through cell division.
Although Cdk1 by itself exerts no detectable influence on viral
replication levels, host cell cyclin-dependent kinases play an
overlapping role with the virus-encoded protein kinase (UL97) in
viral replication. Specific inhibitors of these host and viral kinases are
used to demonstrate that Cdk1 is necessary and sufficient to drive
pseudomitosis; however, viral as well as cell cycle regulated kinases
are important for efficient viral replication.peak levels (7% at 72 h postinfection) compared to
AD169varATCC. The only known difference between these
strain variants is in the UL36 gene product, which has a point
mutation that renders the viral inhibitor of caspase 8
activation nonfunctional [43], suggesting that viral genetic
determinants such as this anti-apoptotic function may impact
this process. All other strains displayed top levels below 5%,
and varied in the timing of maximal pseudomitosis levels,
with Toledo and TownevarATCC peaking at 72 h post-
infection but TownevarRIT and TB40/E showing highest
levels at 50 h postinfection. Thus, although induction of
pseudomitosis is a common property of CMV strains in
culture, AD169varATCC exhibits substantially higher levels
than the other strains we examined.
Cdk1 Is Necessary and Sufficient to Promote
Pseudomitosis during Infection
The levels of endogenous Cdk1 were induced 30% more in
AD169varATCC than in AD169varDE infected cells (Figure
2A), consistent with a role for this cyclin-dependent kinase in
driving pseudomitosis levels. To determine the extent to
which Cdk1 activity alone contributed to the development of
pseudomitosis, retrovirus-transduced HFs expressing en-
hanced green ﬂuorescent protein (GFP), a GFP-tagged, wild-
type Cdk1 (Cdk1wt-GFP) or a GFP-tagged, kinase inactive and
dominant negative Cdk1 (Cdk1dn-GFP) [31] were infected
with AD169varATCC or AD169varDE (MOI of 10). Immuno-
blot analysis showed that both endogenous (black arrowhead)
and recombinant Cdk1 (Cdk1wt-GFP or Cdk1dn-GFP; gray
arrowhead) were comparably expressed in infected cells at 72
h postinfection (Figure 2A). In all experimental settings,
AD169varATCC induced endogenous Cdk1 to higher levels
than AD169varD E ,a n d ,i n d e p e n d e n to ft h er e t r o v i r u s
construct, transduction reduced endogenous Cdk1 levels by
20% to 30%. Cdk1dn-GFP or Cdk1wt-GFP was also expressed
in cells infected with AD169varATCC or AD169varDE, with
levels appearing to be substantially higher in AD169varDE-
infected cells transduced with either construct. Total
(endogenous plus transduced) Cdk1 levels were approxi-
mately 80% in AD169varATCC- and 160% in AD169varDE-
infected cells compared to nontransduced cells. No differ-
ence was observed in the expression of Cdk1wt-GFP or
Cdk1dn-GFP in cells infected with either virus; however,
expression was twice as high in AD169varDE-infected cells,
suggesting a level of variation in total Cdk1 levels that was not
explored further.
GFP ﬂuorescence was detectable in 90% to 100% of
transduced HFs (Figure 2B) and facilitated differentiation
between the round, anucleated pseudomitotic cells and the
spindle-shaped, nucleated cells that retained an interphase
appearance (Figure 2B, insets). Because of the differences in
endogenous and transduced Cdk1 expression levels depend-
ing on the strain variant, comparisons were made within a
variant, although Cdk1 inhibition or overexpression had
similar effects on both AD169varATCC- and AD169varDE-
infected HFs when IE1/IE2 antigen–positive, GFP-positive,
pseudomitotic cells were counted (Figure 2C). High levels of
pseudomitotic cells were observed in AD169varATCC-in-
fected HFs following transduction with Cdk1wt-GFP. By
contrast, such cells were rare in cultures that had been
transduced with Cdk1dn-GFP. When four independent
experiments were analyzed together, the peak levels of
pseudomitosis in either AD169varATCC- (28 6 2%) or
AD169varDE- (7 6 1%) infected cultures were reduced
approximately 4-fold in the presence of Cdk1dn-GFP,
indicating that Cdk1 activity was necessary for this process.
Conversely, transduction of Cdk1wt-GFP, which increased the
total cellular pool of active Cdk1, induced pseudomitosis 1.4-
fold with AD169varATCC and 2.5-fold with AD169varDE,
consistent with expression levels (Figure 2A). Pseudomitosis
levels in GFP controls were similar to levels in nontransduced
cells, indicating a neutral impact of GFP expression on this
process. Thus, Cdk1 appears necessary and sufﬁcient for
induction of pseudomitosis in CMV-infected cells, consistent
with its role in regulating mitosis in the conventional cell
cycle [31].
Cdk1 and Pseudomitosis Are Dispensable for Viral
Replication
To assess the impact of pseudomitosis on viral yields, CMV
(AD169varATCC) released into culture supernatants was
titered at 50, 72, 96, and 120 h postinfection, comparing
nontransduced HFs to HFs transduced with GFP, Cdk1dn-
GFP, or Cdk1wt-GFP (Figure 2D). No differences in virus
titers were observed at any time in any of these conditions
despite the dramatic impact that modulation of Cdk1 levels
had on pseudomitosis. In separate experiments, nontrans-
duced HFs or HFs transduced with GFP, Cdk1dn-GFP, or
Cdk1wt-GFP and infected with AD169varATCC or AD169-
varDE were found to produce similar amounts of virus at 72 h
Figure 1. Pseudomitosis Levels Induced by Commonly Used CMV Strains
Confluent HFs infected with the indicated CMV strains for 50, 72, and 96
h were immunostained with monoclonal antibodies (mAb) against c-
tubulin 1 and against IE1/IE2. The percentage of IE1/IE2
þ pseudomitotic
cells was determined after counting at least 500 cells for each strain at
each time point [7]. Mean percentages and standard deviation from a
representative experiment are shown.
doi:10.1371/journal.ppat.0030006.g001
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e6 0016
Cdk1 Role in Cytomegalovirus Pathogenesispostinfection (Figure 2E). Thus, the dramatic modulation of
pseudomitosis that was observed using these vectors did not
contribute to altered virus replication or release. Therefore,
pseudomitosis is a reﬂection of induced Cdk1 activity during
infection, but viral replication proceeds with equal efﬁciency
in HFs regardless of Cdk1 activity.
Viral Replication Depends on the Activity of Cellular
Kinases
Given that Cdk1 activity does not inﬂuence CMV repli-
cation levels, we evaluated the impact of IMO, a Cdk1/Cdk2/
Cdk5/Cdk9 inhibitor [28], on CMV replication (MOI ¼ 10) at
24, 48, 72, 96, 120, and 144 h postinfection. IMO has been
used to inhibit wild-type and drug-resistant strains of HIV-1
in culture [29], but its antiviral effects against CMV or other
herpesviruses had never been tested. Enzyme inhibition
studies suggested IMP is a more potent and speciﬁc Cdk1
and Cdk2 inhibitor than roscovitine [28,44]. Appearance of
progeny virus in culture supernatants was delayed at 5 lM
IMO and signiﬁcantly inhibited at 10 lM IMO regardless of
whether AD169varATCC or AD169varDE was used (Figure
3A). DMSO (the IMO solvent) at 1% or 2% had no impact on
virus levels. The maximum effect of 5 lM IMO (200- to 300-
fold reduction) was observed at 72 h postinfection, although
viral levels continued to rise. Peak viral yields were obtained
at 120 h postinfection, with a delay of 24 h and a 5-fold
reduction in titer compared to DMSO-treated cultures. IMO
10 lM inhibition was more dramatic, with a greater than a
10,000-fold reduction at 72 h and greater than 20-fold
reduction at 144 h postinfection (Figure 3A). The IMO-
speciﬁc impact on pseudomitosis could not be assessed
because DMSO, the solvent, at either 1% or 2% blocked this
process via a mechanism that has not been explored. IMO at 5
or 10 lM (or DMSO solvent alone up to 2%) in medium
replaced daily had no effect on uninfected cell viability or
total numbers over a 5-d time course (unpublished data).
Numbers of virus-infected HFs started to decline between 72
and 96 h postinfection, but this has been considered a normal
consequence of infection [45] and the intensity and rate of
cell loss were not increased by treatment. Staining with
Hoechst 44432 showed that nuclei were intact and presented
no evidence of pseudomitosis or other changes in nuclear or
chromatin morphology.
Finally, we investigated the effects of combining speciﬁc
Cdk1 inhibition and IMO treatment on viral replication.
Neither IMO (10 lM) nor DMSO (2%) alone altered levels of
viral replication in GFP-, Cdk1wt-GFP–, or Cdk1dn-GFP–
transduced HFs above those expected of IMO alone (Figure
3B). Expression of transduced proteins was not altered by
IMO or DMSO treatment, although pseudomitosis was
completely blocked in all of these conditions (unpublished
data). Thus, Cdk1 does not independently contribute to viral
replication in any of the conditions we used, while a broader
set of cellular kinase activities is important for efﬁcient viral
cycle progression.
Figure 2. Impact of Cdk1 on Pseudomitosis and Replication
(A) Immunoblot analysis of Cdk1 expression in protein extracts from nontransduced ( ) and GFP-, Cdk1wt-GFP , or Cdk1dn-GFP transduced HFs
infected with AD169varATCC (AC) or AD169varDE (DE) for 72 h. The blot was incubated with an anti-Cdk1 monoclonal antibody (mAb) as described in
Materials and Methods. Expected molecular weights: 34 kDa for Cdk1 and 61 kDa for Cdk1wt or dn-GFP. Black arrowhead, endogenous Cdk1; gray
arrowhead, recombinant Cdk1.
(B) GFP fluorescence images of HFs transduced with retroviruses expressing GFP, Cdk1wt-GFP, or Cdk1dn-GFP and infected with AD169varATCC for 72
h (original magnification350). Higher magnification images (3200) are displayed in the insets. Arrowheads indicate representative pseudomitotic cells;
arrows indicate interphase cells.
(C) Percentage of IE1/IE2
þ and GFP
þ pseudomitotic cells in GFP-, Cdk1wt-GFP , or Cdk1dn-GFP transduced HFs infected with AD169varATCC or
AD169varDE for 72 h. Mean percentages and standard deviation from four independent experiments are shown.
(D) Viral yields from nontransduced ( ) and GFP-, Cdk1wt-GFP , or Cdk1dn-GFP transduced HFs infected with AD169varATCC for 50, 72, 96, and 120 h
in one representative experiment.
(E) Viral yields from nontransduced ( ) and GFP-, Cdk1wt-GFP , or Cdk1dn-GFP transduced HFs infected with AD169varATCC or AD169varDE for 72 h in
two independent experiments.
doi:10.1371/journal.ppat.0030006.g002
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Treatment of CMV-infected HFs with 10 lM IMO reduced
but did not completely block replication levels, a pattern
similar to that observed with cells infected with UL97
mutants [32,34,35] or treated with MBV, a potent inhibitor
of the UL97-encoded VPK [41,46–48]. Thus, we investigated
the combined impact of simultaneously inhibiting cellular
Cdks and VPK. To evaluate the contribution of VPK, we
titered progeny virus levels released in the supernatant of
conﬂuent AD169varATCC-infected HFs that were treated
with IMO alone, MBV alone, or combinations of these two
inhibitors. IMO was used at the two previously evaluated
concentrations (5 lM and 10 lM) in the absence of MBV or
together with MBV at subinhibitory (0.025, 0.1, or 0.4 lM)
concentrations. Drug-containing medium was replaced daily,
and virus titers were determined at 24, 48, 72, 96, and 144 h
postinfection (Figure 4). As expected from work describing
the activity of this antiviral drug on HFs [49], addition of
MBV alone at 0.025 or 0.1 lM did not inhibit viral levels and
addition of MBV at 0.4 lM reduced viral levels only 2- to 3-
fold. MBV substantially enhanced the antiviral activity of
IMO in a dose- and time-dependent manner. The most
dramatic effects on viral replication were achieved in the
presence of 5 or 10 lM IMO plus 0.4 lM MBV. Speciﬁcally,
there was a 500-fold enhancement of antiviral activity when
10 lM IMO was used together with 0.4 lM MBV at 72, 96, and
144 h postinfection. These results highlight the dramatic
dependence of CMV replication on the activity of both
cellular and viral protein kinases. Furthermore, these results
demonstrate the potential therapeutic beneﬁt of combining
cellular Cdk and VPK inhibitors to treat CMV infections.
Discussion
Whereas the aberrant process leading to pseudomitosis is
dependent on Cdk1 levels, replication of CMV appears to
require overlapping contributions of Cdks and VPKs. The
synergism of a speciﬁc inhibitor of CMV VPK and a broad
inhibitor of Cdks best illustrated this interdependence. The
CMV VPK inhibitor MBV inhibits viral replication in culture,
showing a pattern that is reminiscent of VPK mutants
[32,34,35]. Herpesvirus-common VPKs are encoded by all
mammalian and avian herpesviruses [33]. In HSV-1 and other
alphaherpesviruses that are studied in actively growing cell
lines, VPKs have been found to be dispensable for replication
even though they impact the phosphorylation status of viral
proteins and are important for viral replication in the host.
In CMV, UL97-encoded VPK provides a critical replication
function in quiescent cells, promoting the efﬁciency of virion
maturation at different steps [32–35]. The variable impact on
viral replication levels together with the fact that a number of
distinct late replication events are sensitive to the absence or
inhibition of VPK is consistent with an overlap in VPK and
Cdk activities, an overlap that gives the impression that VPK
is dispensable in some herpesviruses such as HSV-1 because
these viruses are propagated in actively growing cell lines.
Similar to the behavior of UL97 mutant virus, the antiviral
effect of MBV is inﬂuenced by culture conditions and
metabolic status of host cells in culture [49]. By exploring
the effects of Cdks and VPK inhibition, we have been able to
dissect the impact of protein kinases in virus-induced cell
cycle dysregulation as well as viral replication. The depend-
ence of CMV-induced pseudomitosis on elevated cellular
Cdk1 activity contrasts with the broader, overlapping role of
Cdks and VPK in replication. Future work will focus on
investigating the behavior of UL97 mutant virus or MBV-
treated wild-type virus in the presence of cellular kinase
inhibitors to further dissect the role of individual kinases in
host cell modulation and viral replication.
Induction of Cdk1 underlies the higher levels of pseudo-
mitosis observed with AD169varATCC and lower levels
observed with AD169varDE, and both may be modulated
with predictable results by transduction of dominant negative
Cdk1 or wt Cdk1. The viral function(s) that inﬂuence the
levels and activity of Cdk1 during infection is unknown, and
as such, levels of pseudomitosis may reﬂect viral regulation of
a gene product that drives or inhibits this process. Virus
strain and/or cell culture conditions clearly inﬂuence
pseudomitosis, and one viral function that may play a role,
based on characterized differences between strain variants
used here, is the cell death suppressor viral inhibitor of
caspase 8 activation [43]. The precise roles played by virus-
Figure 3. AD169varATCC and AD169varDE Yields Depend on the Activity of Cellular Kinases
(A) Mean viral yields with standard deviations (three independent experiments) from HFs infected with AD169varATCC or AD169varDE in the presence
of 1% or 2% DMSO or in the presence of 5 lMo r1 0lM IMO for 24, 48, 72, 96, 120, and 144 h.
(B) Viral yields from GFP-, Cdk1wt-GFP , or Cdk1dn-GFP expressing HFs infected with AD169varATCC in the presence of 2% DMSO or 10 lM IMO for 24,
48, 72, 96, and 120 h from one representative experiment.
doi:10.1371/journal.ppat.0030006.g003
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however, interplay between the viral inhibitor of caspase 8
activation and cell cycle dysregulation has not been estab-
lished. Further understanding will come from the use of
additional viral mutants, from the continued study of viral
strains with high or low pseudomitotic behavior, and from
studies that aim at dissecting the Cdk1-dependent events that
are critical to the process. Transduction of wild-type Cdk1
induces levels of pseudomitosis as high as 50%, whereas use of
dominant negative Cdk1 reduces levels to below 1% without
either treatment altering overall virus yields. These data
demonstrate that dysregulation of the cell cycle is associated
and compatible with CMV replication but that the virus does
not rely on this process for any step in replication. It is likely,
though, that this virus might require a range of cellular
functions that are made available as a result of driving cells
into an M-like state. The efﬁciency of CMV replication in
pseudomitotic cells will become better understood by closer
examination of maturation events in these nonnucleated
cells. It is worth noting that, although current models of
envelopment assume the presence of a nuclear membrane,
t h e ya r ec o m p a t i b l ew i t hc a p s i da s s e m b l ya n dv i r i o n
maturation proceeding through the envelopment step in
the absence of a nuclear membrane [33,50].
In CMV-infected HFs, Cdk1/cyclin B induction occurs very
early, by 8 h postinfection, and this induction is maintained
throughout the time course of infection. There appear to be
speciﬁc virus-induced mechanisms, including the accumula-
tion of cyclin B1, the inactivation of negative Cdk1 regulators
such as Myt1 and Wee1, and the accumulation of Cdk1-
activating proteins like Cdc25 [18], that provide speciﬁc
signals to sustain this complex. Despite this, the Cdk1/cyclin B
complex by itself does not support CMV replication. Cdk1/
cyclin B activation and phosphorylation of speciﬁc substrates
have also been reported during infection with other
herpesvirus, such as human herpesvirus 7 [51] and Epstein-
Barr virus [52]. In HSV-1–infected cells, Cdk1 activity is
increased [53] and is required to ensure optimal expression of
speciﬁc late viral genes [54] but also does not affect viral
yields. Except for the reported role of Cdk2 in CMV
replication [15] and some previous evaluation of MBV [49],
there has been little reported investigation of Cdks acting
alone or together with viral kinases in the replication of other
herpesviruses.
All herpesviruses encode protein kinases which appear to
speciﬁcally phosphorylate the same amino acid target
sequences recognized by Cdk1 [55]. Although the physiolog-
ical signiﬁcance of this molecular mimicry is still unclear, it
has been suggested that the viral protein kinases may
facilitate capsid transport across the nuclear membrane by
phosphorylating key components of the nuclear lamina that
are also Cdk1 substrates. Consistent with this hypothesis, a
CMV UL97 mutant virus exhibits a severely impaired ability
to traverse the nuclear envelope [32] under culture con-
ditions where critical roles in DNA replication and encapsi-
dation are apparently supported by cellular kinases such as
Cdks [32,34,35].
Compensatory, overlapping activities of VPK and major
Cdks may be important much earlier in infection than VPK
mutants indicate. The induction of Cdks at early times
postinfection has been associated with accurate processing
and accumulation of IE1, IE2, UL36, and UL37x1 transcripts
[14] as well as with the hyperphosphorylation of the RNA
polymerase II C-terminus [56], functions that are important
well before the late phase of replication and that may also be
carried out by VPK, a virion tegument protein that is
introduced into cells upon entry. Even though pseudomitosis
has brought focus to the late phase of replication, the
coordinated function of viral and cellular kinases likely
contributes to regulation from the initial stages through the
late stages of replication. This has suggested broad potential
for antiviral strategies targeting Cdks, whether applied to
viruses that require dividing cells, such as adenoviruses and
papillomaviruses, or to viruses that replicate in nondividing
cells, such as HIV-1 and herpesviruses [57]. Cdk inhibitors
that range in speciﬁcity (roscovitine, ﬂavopiridol, olomucine,
Figure 4. Checkerboard Analysis of Cellular Cdk Inhibitor IMO and VPK Inhibitor MBV on Viral Yields
Mean infectivity (with standard deviation of four replicates indicated by error bars) determined by plaque assay on culture supernatants of HFs at 24, 48,
72, 96, and 144 h postinfection with AD169varATCC in the presence of 0, 5, or 10 lM IMO (left) or in combination with different concentrations of MBV
(0.025, 0.1, and 0.4 lM) from one experiment.
doi:10.1371/journal.ppat.0030006.g004
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predicted to synergize with MBV in clinically relevant
settings.
Here, we demonstrate the potential for therapeutic
targeting of viral and cellular kinases using IMO after ﬁrst
showing it has prominent antiviral effects against CMV. This
is particularly important considering that indirubins are
already successfully used to treat leukemia [58]. In addition,
the synergistic antiviral effects of IMO and MBV shown here
suggest that a combination of both drugs could be useful to
simultaneously target CMV infection as well as cell prolifer-
ation related to cancer. This may prove particularly attractive
in certain patient populations where both CMV disease and
leukemia are threats, such as leukemic patients recovering
from blood and marrow allografts.
Materials and Methods
Cells and viruses. Primary HFs and the 293T cell line (a gift of Dr.
Jerry Crabtree, Stanford University) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; GIBCO/Invitrogen, http://www.
invitrogen.com) supplemented with 10% Fetal Clone III (HyClone,
http://www.hyclone.com), penicillin G (100 U/ml), streptomycin sulfate
(100 lg/ml), L-arginine (0.58 mg/ml), L-glutamine (1.08 mg/ml), and L-
asparagine (180 lg/ml), here referred to as medium, as described
previously [7,45]. Human CMV strain AD169varATCC (lot 22) was
obtained from American Type Culture Collection (ATCC, http://
www.atcc.com), AD169varDE from Dr. M. Mach (Institute fu ¨r
Virologie, Erlangen, Germany), TownevarATCC from Dr. G. Kemble
(MedImmune, Mountain View, California, United States), Town-
evarRIT3 from M. Stinski (University of Iowa, Iowa City, Iowa, United
States), Toledo from Dr. S. Plotkin (Philadelphia, Pennsylvania,
United States), and TB40/E from Dr. C. Sinzger (Institute fu ¨r
Virologie, Tu ¨bingen, Germany). Propagation and puriﬁcation of all
strains were as described [59]. Virus titers were determined by plaque
assay on HF monolayers in six- or 12-well tissue culture plates.
HF infection with CMV, IMO, and MBV treatments. HF mono-
layers were infected at conﬂuency (day 3 postseeding) with puriﬁed
virions [7] at an MOI of 10. After virus adsorption for 1 h at 37 8Ci n
5% CO2, the inoculum was removed, and the cells were washed twice
with medium prior to the addition of fresh medium. For IMO
treatment, medium containing 5 lMo r1 0lM IMO or containing 1%
or 2% DMSO as control was added to cells after the second wash and
replaced every 24 h. IMO was purchased from Sigma (http://www.
sigmaaldrich.com) and was dissolved in DMSO (Sigma) at a stock
concentration of 1 mM. MBV (GlaxoSmithKline, http://www.gsk.com)
was used as described [49] alone or in combination with IMO.
Retrovirus production and cell transduction. Cdk1wt and Cdk1dn
were ampliﬁed by PCR from plasmids pCMV-Cdc2-WT or pCMV-
Cdc2-D146N (a gift from Dr. S. Van den Heuvel, MGH Cancer
Center, Harvard Medical School, Charlestown, Massachusetts, United
States) using primers speciﬁc for the 59 and 39 nucleotide sequence of
Cdk1 and containing the BamH1 restriction endonuclease recog-
nition site. Primer sequences were as follows: 59-TCggatccATGGAA-
GATTATA-39 and 59-ggatccGACTTCTTAATCTGATTG-39 (BamH1
site in lowercase). PCR bands were inserted in the pCR 2.1-TOPO
vector of the TOPO TA Cloning kit (Invitrogen, http://www.
invitrogen.com) following the manufacturer’s instructions. pCR 2.1-
Cdk1wt and pCR 2.1-Cdk1dn were subsequently digested with
BamH1, and DNA fragments corresponding to Cdk1wt and Cdk1dn
were ligated to the BamH1-digested plasmid LNCX-GFP [45],
generating the constructs LNCX-Cdk1wt-GFP and LNCX-Cdk1dn-
GFP with each Cdk1 inserted in frame with the nucleotide sequence
coding for the N-terminus of GFP. The correct sequence of both
constructs was conﬁrmed by nucleotide sequencing (Stanford Protein
and Nucleic Acid Facility). To generate retroviral particles, 293T cells
were co-transfected with LNCX-GFP or LNCX-Cdk1wt-GFP or
LNCX-Cdk1dn-GFP together with plasmids JK3, LTRVSVG, and
CMVtat. Cell supernatants were collected at 48 h posttransfection,
and retroviral particles were puriﬁed and concentrated by ultra-
centrifugation at 24,000 rpm for 1 h at 4 8C using a SW28 rotor in a
Beckman ultracentrifuge (Beckman Coulter, http://www.
beckmancoulter.com). Pelleted viral particles were suspended in
medium, aliquoted, and stored at 80 8C. For retrovirus transduction,
conﬂuent HFs were split at a 1:2 ratio on day 0 and again at a 1:4 ratio
on day 1. At 24 h after the second seeding, cells were exposed to the
ﬁrst inoculum of retroviral particles, in the presence of 5 lg/ml
Polybrene (Sigma). Then, 5 h later, cells were washed with fresh
medium and a second inoculum was applied for another 5 h. At 24 h
after removal of the second inoculum, cells were tested for GFP,
Cdk1wt-GFP, or Cdk1dn-GFP expression before infection with CMV
as described above.
Immunoﬂuorescence analyses and imaging. c-Tubulin 1 and IE1/
IE2 double staining was carried out as described [7]. Phase-contrast
micrographs of GFP
þ live cells were obtained with a Nikon Eclipse
TE300/200 inverted microscope. For the visualization of GFP and IE1/
IE2 double-positive pseudomitotic cells, samples were ﬁxed with 1%
paraformaldehyde in PBS for 15 min at room temperature,
permeabilized, and blocked as described [7] before staining with an
unconjugated monoclonal antibody against IE1/IE2 (1:800, MAb810;
Chemicon, http://www.chemicon.com) followed by a Texas red–
conjugated goat anti-mouse antibody (1:100; Vector Laboratories,
http://www.vectorlabs.com). Cellular DNA was highlighted with
Hoechst 33342 (Molecular Probes, http://www.invitrogen.com). Cover-
slips were mounted and analyzed as described [7].
Immunoblot analysis. Cells were suspended in lysis buffer
containing 50 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 5% b-
mercaptoethanol, 25 mM sodium ﬂuoride, 1 mM sodium orthovana-
date, and 1 mM phenylmethylsulfonyl ﬂuoride. Samples were boiled
for 5 min, separated by SDS–polyacrylamide gel electrophoresis
through a 7.5% gel, transferred to a polyvinylidene diﬂuoride
membrane (Millipore, http://www.millipore.com), and incubated with
an anti-Cdk1 monoclonal antibody (1:200; Santa Cruz Biotechnolo-
gies, http://www.scbt.com) for 1 h at room temperature before
incubation with a horseradish peroxidase–conjugated goat anti-
mouse secondary antibody for another hour. Signal was developed by
enhanced chemiluminescence (Pierce Biotechnology, http://www.
piercenet.com).
Checkerboard titration of MBV-IMO drug combinations. HFs
(passage 11) were seeded onto 24-well culture plates and maintained
in medium until conﬂuent at a density of 1.9 3 10
5 cells per well.
Wells were inoculated with 2310
6 PFU (in 0.5 ml) of AD169varATCC
(MOI ¼ 10). Virus was adsorbed for 1 h at 37 8Ci n5 %C O 2, and the
inoculum was removed and replaced with 0.5 ml of fresh medium
containing combinations of MBV at 0, 0.025, 0.1, and 0.4 lM and IMO
at 0, 5, and 10 lM in a checkerboard layout. At 24, 48, 72, 96, and 144
h after inoculation, the culture supernatant was harvested from each
well, mixed with 0.5% sterile milk, and frozen at  80 8C until virus
titers were determined by plaque assay. Fresh medium containing
freshly made drug combinations was replaced in each culture wells
until the next collection time point. The checkerboard experiment
was performed in triplicate.
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